

Supplementary Material to "Safety and Efficacy of Elosulfase Alfa in Australian Patients with Morquio A Syndrome: A Phase 3b Study"

Supplementary file 3. Frequently reported drug-related adverse events by Preferred Term

Adverse event	Elosulfase alfa (N=13)
Diarrhea	7 (53.8%)
Vomiting	7 (53.8%)
Pyrexia	6 (46.2%)
Nasopharyngitis	5 (38.5%)
Pain in extremity	5 (38.5%)
Headache	4 (30.8%)
Abdominal pain	3 (23.1%)
Abdominal pain upper	3 (23.1%)
Cough	3 (23.1%)
Nausea	3 (23.1%)
Tachycardia	3 (23.1%)
Arthralgia	2 (15.4%)
Catheter site erythema	2 (15.4%)
Dizziness	2 (15.4%)
Hypotension	2 (15.4%)
Joint stiffness	2 (15.4%)
Oropharyngeal pain	2 (15.4%)
Seasonal allergy	2 (15.4%)
Seizure	2 (15.4%)
Viral upper respiratory tract infection	2 (15.4%)